同社は、医療機関と特定細胞加工物「S-DSC(R)」の製造委受託に係る契約を締結し、これまで受託体制の整備等を進めてきたが、今回、医療機関における本治療の提供体制の整備、並びに同社における医療機関からの製造受託実施に向けた準備が整ったことから、「S-DSC(R)」の製造受託を開始する。On the 8th, Medinet announced that they will begin manufacturing specific cell processed products used for the treatment of male and female pattern baldness using cultivated self-hair ball part hair root sheath cells.
This treatment involves taking DSC cells from the hair follicle sheath (DSC) of the scalp that has not been depilated, expanding the cells in vitro, and administering the resulting specific cell processed product (S-DSC (R)) to the depilated area.
In recent years, research on hair regeneration for the purpose of treating baldness has been progressing. The results have shown that by culturing DSC cells, which are considered essential for the growth of hair papilla, underneath the scalp and administering them as "S-DSC(R)", it may stimulate hair growth.
While the company has signed contracts for the manufacturing commission and specific cell processed product "S-DSC(R)" with medical institutions and has been working on the development of the commission system, this time, the preparation for the provision of the treatment system in medical institutions and the implementation of commissioning manufacturing from medical institutions in the company is ready, and they will start manufacturing "S-DSC(R)".
The technology for "S-DSC(R)" is provided by Shiseido Company, Limited Sponsored ADR and the correct manufacturing process is supervised by Shiseido, and it's properly manufactured at the Medinet production facility.
